Elicitation of health state utilities associated with the mode of administration of drugs acting on the prostacyclin pathway in pulmonary arterial hypertension

References

• LajoieACBonnetSProvencherSCombination therapy in pulmonary arterial hypertension: recent accomplishments and future challengesPulm Circ20177231232528597774
   PubMed Web of Science ®Google Scholar
• McLaughlinVVMcGoonMDPulmonary arterial hypertensionCirculation2006114131417143117000921
   PubMed Web of Science ®Google Scholar
• ShafazandSGoldsteinMKDoyleRLHlatkyMAGouldMKHealth-related quality of life in patients with pulmonary arterial hypertensionChest200412651452145915539712
   PubMed Web of Science ®Google Scholar
• FlatteryMPPinsonJMSavageLSalyerJLiving with pulmonary artery hypertension: patients’ experiencesHeart Lung20053429910715761454
   PubMed Web of Science ®Google Scholar
• RichSA new classification of pulmonary hypertensionAdv Pulm Hypertens20021136
   Google Scholar
• GalièNHumbertMVachieryJL2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)Eur Heart J20153716711926320113
   PubMed Web of Science ®Google Scholar
• D’AlonzoGEBarstRJAyresSMSurvival in patients with primary pulmonary hypertension. Results from national prospective registryAnn Intern Med199111553433491863023
   PubMed Web of Science ®Google Scholar
• FarberHWMillerDPPomsADFive-year outcomes of patients enrolled in the REVEAL RegistryChest201514841043105426066077
   PubMed Web of Science ®Google Scholar
• HumbertMGhofraniHAThe molecular targets of approved treatments for pulmonary arterial hypertensionThorax2016711738326219978
   PubMed Web of Science ®Google Scholar
• GalièNBarberàJAFrostAEInitial use of ambrisentan plus tadalafil in pulmonary arterial hypertensionN Engl J Med2015373983484426308684
   PubMed Web of Science ®Google Scholar
• SitbonOGaineSBeyond a single pathway: combination therapy in pulmonary arterial hypertensionEur Respir Rev20162514240841727903663
   PubMed Web of Science ®Google Scholar
• PulidoTAdzerikhoIChannickRNMacitentan and morbidity and mortality in pulmonary arterial hypertensionN Engl J Med2013369980981823984728
   PubMed Web of Science ®Google Scholar
• LangIMGaineSPRecent advances in targeting the prostacyclin pathway in pulmonary arterial hypertensionEur Respir Rev20152413863064126621977
   PubMedGoogle Scholar
• GuillevinLArmstrongIAldrighettiRUnderstanding the impact of pulmonary arterial hypertension on patients’ and carers’ livesEur Respir Rev20132213053554224293469
   PubMedGoogle Scholar
• European Pulmonary Hypertension AssociationThe impact of pulmonary arterial hypertension (PAH) on the lives patients and carers: results from an international survey2012 Available from: http://www.phaeurope.org/wp-content/uploads/International-PAH-patient-and-Carer-Survey-Report-FINAL1.pdfAccessed October 1, 2017
   Google Scholar
• MubarakKKA review of prostaglandin analogs in the management of patients with pulmonary arterial hypertensionRespir Med2010104192119683911
   PubMed Web of Science ®Google Scholar
• HumbertMSanchezOFartoukhMShort-term and long-term epoprostenol (prostacyclin) therapy in pulmonary hypertension secondary to connective tissue diseases: results of a pilot studyEur Respir J19991361351135610445611
   PubMed Web of Science ®Google Scholar
• KallenAJLedermanEBalajiABloodstream infections in patients given treatment with intravenous prostanoidsInfect Control Hosp Epidemiol200829434234918462147
   PubMed Web of Science ®Google Scholar
• SimonneauGBarstRJGalieNTreprostinil Study GroupContinuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trialAm J Respir Crit Care Med2002165680080411897647
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration’s (FDA) Patient-Focused Drug Development InitiativeThe Voice of the Patient: Pulmonary Arterial Hypertension5132014 Available from: https://www.fda.gov/downloads/forindustry/userfees/prescriptiondruguserfee/ucm429382.pdfAccessed October 1, 2017
   Google Scholar
• UptraviSummary of product characteristics62017 Available from: https://www.medicines.org.uk/emc/medicine/31963Accessed October 1, 2017
   Google Scholar
• Uptravi^® (selexipag) tablets [prescribing information]SwitzerlandActelion Pharmaceuticals Ltd2015 Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/207947s000lbl.pdfAccessed October 1, 2017
   Google Scholar
• Canadian Agency for Drugs and Technologies (CADT)Guidelines for the Economic Evaluation of Health Technologies: Canada4th edOttawaCanadian Agency for Drugs and Technologies2017
   Google Scholar
• Pharmaceutical Benefits Advisory CommitteeGuidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (version 5.0)CanberraAustralian Government Department of Health and Ageing2016
   Google Scholar
• NICE (National Institute for Health and Care Excellence)Process and methods guides, Guide to the methods of technology appraisalLondonNational Institute for Health and Care Excellence2013
   Google Scholar
• DrummondMFSculpherMJClaxtonKMethods for the Economic Evaluation of Health Care ProgrammesNew YorkOxford University Press2015
   Google Scholar
• BrazierJRatcliffeJSalomanJTsuchiyaAMeasuring and Valuing Health Benefits for Economic EvaluationNew YorkOxford University Press2017
   Google Scholar
• FeenyDPreference-based measures: utility and quality-adjusted life yearsFayersPHaysRAssessing Quality of Life in Clinical Trials22nd edNew YorkOxford University Press2011405431
   Google Scholar
• BenzaRLMillerDPBarstRJBadeschDBFrostAEMcGoonMDAn evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL RegistryChest2012142244845622281797
   PubMed Web of Science ®Google Scholar
• WapnerJMaturaLAAn update on pulmonary arterial hypertensionJ Nurse Pract201511555155925954140
   PubMedGoogle Scholar
• McLaughlinVVShahSJSouzaRHumbertMManagement of pulmonary arterial hypertensionJ Am Coll Cardiol201565181976199725953750
   PubMed Web of Science ®Google Scholar
• McLaughlinVVArcherSLBadeschDBAmerican College of Cardiology Foundation Task Force on Expert Consensus DocumentsAmerican Heart AssociationAmerican College of Chest PhysiciansAmerican Thoracic Society, IncPulmonary Hypertension AssociationACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on expert consensus documents and the American Heart Association developed in collaboration with the American College of Chest Physicians; American Thoracic Society, Inc.; and the Pulmonary Hypertension AssociationJ Am Coll Cardiol200953171573161919389575
   PubMed Web of Science ®Google Scholar
• RowenDBrazierJTsuchiyaAYoungTIbbotsonRIt’s all in the name, or is it? The impact of labeling on health state valuesMed Decis Making2012321314021685376
   PubMed Web of Science ®Google Scholar
• van ReenenMJanssenBEQ-5D-5L User Guide. Version 2.142015 Available from: http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/EQ-5D-5L_UserGuide_2015.pdfAccessed February 7, 2017
   Google Scholar
• TorranceGWThomasWHSackettDLA utility maximization model for evaluation of health care programsHealth Serv Res1972721181335044699
   PubMedGoogle Scholar
• OppeMDevlinNJvan HoutBKrabbePFde CharroFA program of methodological research to arrive at the new international EQ-5D-5L valuation protocolValue Health201417444545324969006
   PubMed Web of Science ®Google Scholar
• BallingerRSMaceyJLloydAJBrazierJUtilities associated with the number of days on parenteral support in the treatment of short bowel syndromeValue Health2016197A513
   Web of Science ®Google Scholar
• KosmasCEShinglerSLSamantaKHealth state utilities for chronic lymphocytic leukemia: importance of prolonging progression-free survivalLeuk Lymphoma20155651320132625213185
   PubMed Web of Science ®Google Scholar
• AttemaAEVersteeghMMOppeMBrouwerWBStolkEALead time TTO: leading to better health state valuations?Health Econ201322437639222396243
   PubMed Web of Science ®Google Scholar
• KindPDolanPGudexCWilliamsAVariations in population health status: results from a United Kingdom national questionnaire surveyBMJ199831671337367419529408
   PubMed Web of Science ®Google Scholar
• Office for National StatisticsOverview of the United Kingdom1152015 Available from: http://www.ons.gov.uk/ons/dcp171776_422383.pdfAccessed July 27, 2017
   Google Scholar
• Office for National Statistics2011 Census: Key Statistics for England and Wales, March 2011 [serial on the Internet]32011 Available from: http://www.ons.gov.uk/ons/dcp171778_290685.pdfAccessed July 27, 2017
   Google Scholar
• Office for National Statistics [webpage on the Internet]Statistical Bulletin: UK Labour Market72017 Available from: https://www.ons.gov.uk/employmentandlabourmarket/peopleinwork/employmentandemployeetypes/bulletins/uklabourmarket/july2017Accessed July 31, 2017
   Google Scholar
• van NootenFEvan ExelNJKoolmanXBrouwerWB“Married with children” the influence of significant others in TTO exercisesHealth Qual Life Outcomes20151319426135391
   PubMed Web of Science ®Google Scholar
• OsborneRHLourençoRDDaltonAQuality of life related to oral versus subcutaneous iron chelation: a time trade-off studyValue Health200710645145617970927
   PubMed Web of Science ®Google Scholar
• ChancellorJAballéaSLawrenceAPreferences of patients with diabetes mellitus for inhaled versus injectable insulin regimensPharmacoeconomics200826321723418282016
   PubMed Web of Science ®Google Scholar
• AleppoG webpage on the InternetInsulin Pump: What to Know Before You DisconnectEndocrineWeb Available from: https://www.endocrineweb.com/guides/how-disconnect-pump-plus-tips-traveling-pump-using-pump-schoolAccessed October 19, 2017
   Google Scholar
• WhiteRJLevinYWessmanKHeiningerAFrutigerKSubcutaneous treprostinil is well tolerated with infrequent site changes and analgesicsPulm Circ20133361162124618545
   PubMed Web of Science ®Google Scholar
• JohnsonESSullivanSDMozaffariELangleyPCBodsworthNJA utility assessment of oral and intravenous ganciclovir for the maintenance treatment of AIDS-related cytomegalovirus retinitisPharmacoeconomics199610662362910164062
   PubMed Web of Science ®Google Scholar
• CleggAJScottDALovemanEThe clinical and cost-effectiveness of left ventricular assist devices for end-stage heart failure: a systematic review and economic evaluationHealth Technol Assess20059451132
   Web of Science ®Google Scholar
• British Thoracic Society (BTS)/Scottish Intercollegiate Guidelines Network (SIGN) [webpage on the Internet]British Guidelines on the Management of Asthma92016 Available from: https://www.brit-thoracic.org.uk/document-library/clinical-information/asthma/btssign-asthma-guideline-2016/Accessed October 20, 2017
   Google Scholar
• KarnonJTolleyKOyeeJJewittKOssaDAkehurstRCost-utility analysis of deferasirox compared to standard therapy with desferrioxamine for patients requiring iron chelation therapy in the United KingdomCurr Med Res Opin20082461609162118439348
   PubMed Web of Science ®Google Scholar
• MatzaLSSapraSJDillonJFHealth state utilities associated with attributes of treatments for hepatitis CEur J Health Econ20151691005101825481796
   PubMed Web of Science ®Google Scholar
• MatzaLSCongZChungKUtilities associated with subcutaneous injections and intravenous infusions for treatment of patients with bone metastasesPatient Prefer Adherence2013785586524039408
   PubMed Web of Science ®Google Scholar
• OsborneRHDaltonAHertelJSchroverRSmithDKHealth-related quality of life advantage of long-acting injectable antipsychotic treatment for schizophrenia: a time trade-off studyHealth Qual Life Outcomes20121013522472127
   PubMed Web of Science ®Google Scholar
• KurzynaMMałaczyńska-RajpoldKKotejaAAn implantable pump Lenus pro® in the treatment of pulmonary arterial hypertension with intravenous treprostinilBMC Pulm Med201717116229195500
   PubMed Web of Science ®Google Scholar
• BourgeRCWaxmanABGomberg-MaitlandMTreprostinil administered to treat pulmonary arterial hypertension using a fully implantable programmable intravascular delivery system: results of the DelIVery for PAH trialChest20161501273427396777
   PubMed Web of Science ®Google Scholar